{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:26:23Z","timestamp":1790472383258,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adenosine deaminase (ADA) deficiency is a systemic metabolic disease that causes an autosomal recessive variant of severe combined immunodeficiency (SCID) and less consistently other complications including neurologic abnormalities. Hematopoietic stem cell transplantation (HSCT) is able to correct the immunodeficiency, whereas control of nonimmunologic complications has not been extensively explored. We applied HSCT in 15 ADA-deficient patients consecutively treated at our institutions since 1982 and analyzed long-term outcome. Seven patients received transplants without conditioning from HLA-matched family donors (MFDs); the other 8 patients received conditioning and were given transplants either from HLA-mismatched family donors (MMFDs; n = 6) or from matched unrelated donors (MUDs; n = 2). At a mean follow-up period of 12 years (range, 4-22 years), 12 patients are alive with stable and complete immune reconstitution (7 of 7 after MFD, 4 of 6 after MMFD, and 1 of 2 after MUD transplantation). Six of 12 surviving patients show marked neurologic abnormalities, which include mental retardation, motor dysfunction, and sensorineural hearing deficit. We were unable to identify disease or transplantation-related factors correlating with this divergent neurologic outcome. The high rate of neurologic abnormalities observed in long-term surviving patients with ADA deficiency indicates that HSCT commonly fails to control CNS complications in this metabolic disease.<\/jats:p>","DOI":"10.1182\/blood-2006-07-034678","type":"journal-article","created":{"date-parts":[[2006,12,22]],"date-time":"2006-12-22T01:54:36Z","timestamp":1166752476000},"page":"3595-3602","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":85,"title":["Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications"],"prefix":"10.1182","volume":"109","author":[{"given":"Manfred","family":"Ho\u0308nig","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Albert","sequence":"additional","affiliation":[{"name":"Dr von Haunersches Kinderspital, Ludwig Maximilians University Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sparber-Sauer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Schu\u0308tz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Belohradsky","sequence":"additional","affiliation":[{"name":"Dr von Haunersches Kinderspital, Ludwig Maximilians University Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayfun","family":"Gu\u0308ngo\u0308r","sequence":"additional","affiliation":[{"name":"Division of Immunology\/Hematology\/BMT, University Children's Hospital, Zu\u0308rich, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus T.","family":"Rojewski","sequence":"additional","affiliation":[{"name":"Institute for Transfusion Medicine, University Hospital of Ulm and Institute for Clinical Transfusion Medicine and Immunogenetics, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Bode","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Pannicke","sequence":"additional","affiliation":[{"name":"Institute for Transfusion Medicine, University Hospital of Ulm and Institute for Clinical Transfusion Medicine and Immunogenetics, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Lippold","sequence":"additional","affiliation":[{"name":"Institute for Transfusion Medicine, University Hospital of Ulm and Institute for Clinical Transfusion Medicine and Immunogenetics, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Institute for Transfusion Medicine, University Hospital of Ulm and Institute for Clinical Transfusion Medicine and Immunogenetics, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Michael","family":"Debatin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hershfield","sequence":"additional","affiliation":[{"name":"Duke Medical Center, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2006,12,21]]},"reference":[{"key":"2019111716411059700_B1","doi-asserted-by":"crossref","unstructured":"Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol2004; 22:625\u2013655.","DOI":"10.1146\/annurev.immunol.22.012703.104614"},{"key":"2019111716411059700_B2","unstructured":"Hirschhorn R. Immunodeficiency disease due to deficiency of adenosine deaminase. In Ochs H (Ed.). Primary immunodeficiency diseases: a molecular & cellular approach1998;Oxford, United Kingdom Oxford University Press pp. 121\u2013139."},{"key":"2019111716411059700_B3","doi-asserted-by":"crossref","unstructured":"Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol2005; 35:25\u201330.","DOI":"10.1002\/eji.200425738"},{"key":"2019111716411059700_B4","doi-asserted-by":"crossref","unstructured":"Stephan JL, Vlekova V, Le Deist F, et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr1993; 123:564\u2013572.","DOI":"10.1016\/S0022-3476(05)80951-5"},{"key":"2019111716411059700_B5","doi-asserted-by":"crossref","unstructured":"Hirschhorn R, Paageorgiou PS, Kesarwala HH, Taft LT. Amelioration of neurologic abnormalities after \u201cenzyme replacement\u201d in adenosine deaminase deficiency. N Engl J Med1980; 303:377\u2013380.","DOI":"10.1056\/NEJM198008143030706"},{"key":"2019111716411059700_B6","doi-asserted-by":"crossref","unstructured":"Tanaka C, Hara T, Suzaki I, Maegaki Y, Takeshita K. Sensorineural deafness in siblings with adenosine deaminase deficiency. Brain Dev1996; 18:304\u2013306.","DOI":"10.1016\/0387-7604(96)00014-9"},{"key":"2019111716411059700_B7","doi-asserted-by":"crossref","unstructured":"Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med1999; 340:508\u2013516.","DOI":"10.1056\/NEJM199902183400703"},{"key":"2019111716411059700_B8","doi-asserted-by":"crossref","unstructured":"Fischer A, Landais P, Friedrich W, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet1990; 336:850\u2013854.","DOI":"10.1016\/0140-6736(90)92348-L"},{"key":"2019111716411059700_B9","doi-asserted-by":"crossref","unstructured":"Dror Y, Gallagher R, Wara DW, et al. Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation. Blood1993; 81:2021\u20132030.","DOI":"10.1182\/blood.V81.8.2021.bloodjournal8182021"},{"key":"2019111716411059700_B10","doi-asserted-by":"crossref","unstructured":"Friedrich W, Goldmann SF, Ebell W, et al. Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donors. Eur J Pediatr1985; 144:125\u2013130.","DOI":"10.1007\/BF00451897"},{"key":"2019111716411059700_B11","doi-asserted-by":"crossref","unstructured":"O'Reilly RJ, Brochstein J, Collins N, et al. Evaluation of HLA-haplotype disparate parental marrow grafts depleted of T lymphocytes by differential agglutination with a soybean lectin and E-rosette depletion for the treatment of severe combined immunodeficiency. Vox Sang1986; 51:suppl 2, 81\u201386.","DOI":"10.1159\/000461564"},{"key":"2019111716411059700_B12","unstructured":"Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood1998; 91:3646\u20133653."},{"key":"2019111716411059700_B13","unstructured":"Hershfield MS. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin Hematol1998; 35:291\u2013298."},{"key":"2019111716411059700_B14","doi-asserted-by":"crossref","unstructured":"Hershfield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol1995; 76:S228\u2013232.","DOI":"10.1016\/S0090-1229(95)90306-2"},{"key":"2019111716411059700_B15","doi-asserted-by":"crossref","unstructured":"Aiuti A, Ficara F, Cattaneo F, Bordignon C, Roncarolo MG. Gene therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol2003; 3:461\u2013466.","DOI":"10.1097\/00130832-200312000-00007"},{"key":"2019111716411059700_B16","doi-asserted-by":"crossref","unstructured":"Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science2002; 296:2410\u20132413.","DOI":"10.1126\/science.1070104"},{"key":"2019111716411059700_B17","doi-asserted-by":"crossref","unstructured":"Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther2006; 14:505\u2013513.","DOI":"10.1016\/j.ymthe.2006.06.007"},{"key":"2019111716411059700_B18","doi-asserted-by":"crossref","unstructured":"Bluetters-Sawatzki R, Friedrich W, Ebell W, et al. HLA-haploidentical bone marrow transplantation in three infants with adenosine deaminase deficiency: stable immunological reconstitution and reversal of skeletal abnormalities. Eur J Pediatr1989; 149:104\u2013109.","DOI":"10.1007\/BF01995857"},{"key":"2019111716411059700_B19","doi-asserted-by":"crossref","unstructured":"Hershfield MS, Fetter JE, Small WC, et al. Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells. J Biol Chem1982; 257:6380\u20136386.","DOI":"10.1016\/S0021-9258(20)65152-3"},{"key":"2019111716411059700_B20","unstructured":"Hershfield MS, Kredich NM, Koller CA, et al. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2\u2032-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine. Cancer Res1983; 43:3451\u20133458."},{"key":"2019111716411059700_B21","doi-asserted-by":"crossref","unstructured":"Comans-Bitter WM, de Groot R, van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr1997; 130:388\u2013393.","DOI":"10.1016\/S0022-3476(97)70200-2"},{"key":"2019111716411059700_B22","doi-asserted-by":"crossref","unstructured":"Arredondo-Vega FX, Santisteban I, Daniels S, Toutain S, Hershfield MS. Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am J Hum Genet1998; 63:1049\u20131059.","DOI":"10.1086\/302054"},{"key":"2019111716411059700_B23","doi-asserted-by":"crossref","unstructured":"Hirschhorn R, Beratis N, Rosen FS, Parkman R, Stern R, Polmar S. Adenosine-deaminase deficiency in a child diagnosed prenatally. Lancet1975; 1:73\u201375.","DOI":"10.1016\/S0140-6736(75)91075-2"},{"key":"2019111716411059700_B24","doi-asserted-by":"crossref","unstructured":"Valerio D, Dekker BM, Duyvesteyn MG, et al. One adenosine deaminase allele in a patient with severe combined immunodeficiency contains a point mutation abolishing enzyme activity. EMBO J1986; 5:113\u2013119.","DOI":"10.1002\/j.1460-2075.1986.tb04184.x"},{"key":"2019111716411059700_B25","unstructured":"Hershfield M. Combined immune deficiencies due to purine enzyme defects. In Stiehm ER (Ed.). Immunologic Disorders in Infants and Children2004; 5th ed Philadelphia, PA WB Saunders pp. 480\u2013504."},{"key":"2019111716411059700_B26","doi-asserted-by":"crossref","unstructured":"Hershfield MS. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat1995; 5:107\u2013112.","DOI":"10.1002\/humu.1380050202"},{"key":"2019111716411059700_B27","doi-asserted-by":"crossref","unstructured":"Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med1987; 316:589\u2013596.","DOI":"10.1056\/NEJM198703053161005"},{"key":"2019111716411059700_B28","doi-asserted-by":"crossref","unstructured":"Chan B, Wara D, Bastian J, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined Immunodeficiency (SCID). Clin Immunol2005; 117:133\u2013143.","DOI":"10.1016\/j.clim.2005.07.006"},{"key":"2019111716411059700_B29","doi-asserted-by":"crossref","unstructured":"Malacarne F, Benicchi T, Notarangelo LD, et al. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur J Immunol2005; 35:3376\u20133386.","DOI":"10.1002\/eji.200526248"},{"key":"2019111716411059700_B30","doi-asserted-by":"crossref","unstructured":"Small TN, Wall DA, Kurtzberg J, Cowan MJ, O'Reilly RJ, Friedrich W. Association of reticular dysgenesis (thymic alymphoplasia and congenital aleukocytosis) with bilateral sensorineural deafness. J Pediatr1999; 135:387\u2013389.","DOI":"10.1016\/S0022-3476(99)70141-1"},{"key":"2019111716411059700_B31","doi-asserted-by":"crossref","unstructured":"Rogers MH, Lwin R, Fairbanks L, Gerritsen B, Gaspar HB. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr2001; 139:44\u201350.","DOI":"10.1067\/mpd.2001.115023"},{"key":"2019111716411059700_B32","doi-asserted-by":"crossref","unstructured":"Keightley RG, Lawton AR, Cooper MD, Yunis EJ. Successful fetal liver transplantation in a child with severe combined immunodeficiency. Lancet1975; 2:850\u2013853.","DOI":"10.1016\/S0140-6736(75)90238-X"},{"key":"2019111716411059700_B33","doi-asserted-by":"crossref","unstructured":"Polmar SH, Stern RC, Schwartz AL, Wetzler EM, Chase PA, Hirschhorn R. Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med1976; 295:1337\u20131343.","DOI":"10.1056\/NEJM197612092952402"},{"key":"2019111716411059700_B34","doi-asserted-by":"crossref","unstructured":"Fairbanks LD, Simmonds HA, Duley JA, Gaspar HB, Flood T, Steward CA. ADA activity and DATP levels in erythrocytes after bone marrow transplantation. Adv Exp Med Biol2000; 486:51\u201355.","DOI":"10.1007\/0-306-46843-3_10"},{"key":"2019111716411059700_B35","doi-asserted-by":"crossref","unstructured":"Hirschhorn R, Roegner-Maniscalco V, Kuritsky L, Rosen FS. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J Clin Invest1981; 68:1387\u20131393.","DOI":"10.1172\/JCI110389"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/8\/3595\/1290881\/zh800807003595.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/8\/3595\/1290881\/zh800807003595.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:58:49Z","timestamp":1628297929000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/109\/8\/3595\/23685\/Patients-with-adenosine-deaminase-deficiency"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,21]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2006,12,21]]},"published-print":{"date-parts":[[2007,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2006-07-034678","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,21]]}}}